EP1043020A1 — Medicinal composition for percutaneous administration
Assigned to Daiichi Pharmaceutical Co Ltd · Expires 2000-10-11 · 26y expired
What this patent protects
A percutaneously absorbable medicinal composition comprising a percutaneous absorption enhancer and at least one member selected from the group consisting of aromatic amidine derivatives represented by formula (1): salts of the derivatives, solvates of the derivatives, and solv…
USPTO Abstract
A percutaneously absorbable medicinal composition comprising a percutaneous absorption enhancer and at least one member selected from the group consisting of aromatic amidine derivatives represented by formula (1): salts of the derivatives, solvates of the derivatives, and solvates of salts of the derivatives. The present invention provides a composition which exhibits high percutaneous absorbability, which can maintain an effective blood level for prolonged periods of time, which provides antithrombotic and anticoagulant effects.
Drugs covered by this patent
- Androgel (TESTOSTERONE) · Besins Hlthcare
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.